US Stands in the Way of LDCs’ Pharmaceutical Transition Period

 Posted by on October 16, 2015  Comments Off on US Stands in the Way of LDCs’ Pharmaceutical Transition Period
Oct 162015
 

wto-logo[Cross posted from the TWN Info Service on Intellectual Property Issues, Link] As the World Trade Organization’s intellectual property body begins its session today, there is emerging consensus among the organization’s members that the poorest nations in the world, the least developed countries (LDCs), should not have to apply or enforce pharmaceutical product patents or to implement ‘mailbox’ or exclusive marketing rights for as long as they remain LDCs.

The WTO Trade-Related Aspects of Intellectual Property Rights Agreement (TRIPS) Council is meeting in Geneva on 15-16 October.

However, whether or not these vulnerable nations will clinch their desired demands very much depends on the United States, which remains opposed to LDCs’ requests. Continue reading »

Share

WTO TRIPS Council To Decide On LDC Pharma Extension, Non-Violation Complaints

 Posted by on October 15, 2015  Comments Off on WTO TRIPS Council To Decide On LDC Pharma Extension, Non-Violation Complaints
Oct 152015
 

ipw-logo[Catherine Saez, IP Watch, Link (CC-BY-NC-SA)] The intellectual property committee of the World Trade Organization is meeting this week with a full agenda. The highlight of the agenda is the extension of a waiver allowing least developed countries to choose not to enforce intellectual property rights on pharmaceutical products. Also high on the agenda is a decision on whether to extend a moratorium banning IP from complaints not linked to any breached WTO agreement, and the annual review of special compulsory licence for exporting pharmaceutical products. Continue reading »

Share

LDCs Be Damned: USTR and Big Pharma seeks to eviscerate Least Developed Countries’ Insulation From Pharmaceutical Monopolies

 Posted by on October 12, 2015  Comments Off on LDCs Be Damned: USTR and Big Pharma seeks to eviscerate Least Developed Countries’ Insulation From Pharmaceutical Monopolies
Oct 122015
 

BrookBakerIn November of 2001, at the height of the global AIDS pandemic, every WTO member country in the world, including the United States, voted unanimously in the Doha Declaration on the TRIPS Agreement and Public Health that WTO Least Developed Countries members should be granted an unconditional extension of any obligation to grant or enforce patents, data protections, or exclusive marketing rights on pharmaceutical products.  These countries desperately needed access to affordable generic medicines and freedom from the pillage of Big Pharma’s monopoly pricing.  This sensible and humane transition policy was confirmed by votes of the WTO TRIPS Council and General Council in 2002. Continue reading »

Share

Joint Letter by Over 70 Civil Society Groups: WTO Is Obliged Under TRIPS Art. 66.1 to Grant LDC Request for TRIPS Extension

 Posted by on June 1, 2015  Comments Off on Joint Letter by Over 70 Civil Society Groups: WTO Is Obliged Under TRIPS Art. 66.1 to Grant LDC Request for TRIPS Extension
Jun 012015
 

wto-logo[Joint Letter from 70 civil society groups to the Members of the World Trade Organization, PDF] As civil society organizations concerned with ensuring prompt availability of affordable medicines in Least Developed Countries (LDCs) we call on WTO Members to unconditionally accord the LDC Group an extension of the transition period with respect to pharmaceutical products and waivers from obligations under Article 70.8 (mailbox obligation) and Article 70.9 (exclusive marketing rights) as requested in their duly motivated request to the TRIPs Council (IP/C/W/605). Continue reading »

Share

UNITAID NGO Delegation Expresses Strong Support for LDC Pharmaceutical Extension Request at WTO TRIPS Council

 Posted by on March 10, 2015  Comments Off on UNITAID NGO Delegation Expresses Strong Support for LDC Pharmaceutical Extension Request at WTO TRIPS Council
Mar 102015
 

BrookBakerThe NGO delegation to the Board of UNITAID offers its strong support for the proposal of WTO least developed country Members to extend the transition period for enforcing protections for pharmaceutical related patents and clinical data “for as long as the WTO member remains a least developed country.”  The proposal, IP/C/W/605, was offered by Bangladesh on behalf of LDCs at the 24-25 February 2015 meeting of the WTO TRIPS Council and will be taken forward at its next 1 June 2015 meeting.

In addition to seeking an unconditional extension of the current pharmaceutical transition period set to expire on 1 January 2016, the LDCs also seek a waiver from the General Council with respect to two additional transition measures, namely mailbox and exclusive marketing rights provisions under Articles 70(8) and 70(9) of the TRIPS Agreement. Continue reading »

Share

TRIPS Council: LDC Extension, Tobacco Plain Packaging Take Centre Stage

 Posted by on March 6, 2013  Comments Off on TRIPS Council: LDC Extension, Tobacco Plain Packaging Take Centre Stage
Mar 062013
 

ictsd-160pxWTO members this week discussed a proposal by least developed countries (LDCs) to extend their transition period for implementing the organisation’s intellectual property rules, which is set to expire this July. Members at the 5-6 March meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) also debated a proposed New Zealand law that would require plain packaging for tobacco products; a similar Australian policy is already facing three separate challenges at the WTO’s Dispute Settlement Body. Continue reading »

Share